Scarica l'app Stockscreener
34.10
4.11%
-1.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$35.56
Aprire:
$35.8
Volume 24 ore:
1.18M
Relative Volume:
1.64
Capitalizzazione di mercato:
$1.27B
Reddito:
$272.30M
Utile/perdita netta:
$-5.14M
Rapporto P/E:
-208.56
EPS:
-0.1635
Flusso di cassa netto:
$42.76M
1 W Prestazione:
-6.19%
1M Prestazione:
-28.50%
6M Prestazione:
-13.50%
1 anno Prestazione:
+53.33%
Intervallo 1D:
$33.74
$36.15
Intervallo di 1 settimana:
$33.74
$37.06
Portata 52W:
$20.85
$54.85
Harrow Inc Stock (HROW) Company Profile
Nome
Harrow Inc
Settore
Telefono
615.733.4731
Indirizzo
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
34.10 | 1.27B | 272.30M | -5.14M | 42.76M | -0.1635 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Iniziato | BTIG Research | Buy |
| 2025-06-10 | Iniziato | William Blair | Outperform |
| 2025-02-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-04 | Reiterato | B. Riley Securities | Buy |
| 2024-04-11 | Iniziato | Craig Hallum | Buy |
| 2022-09-08 | Ripresa | B. Riley Securities | Buy |
| 2021-10-14 | Ripresa | B. Riley Securities | Buy |
| 2021-09-24 | Iniziato | Aegis Capital | Buy |
| 2021-07-02 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Harrow Inc Borsa (HROW) Ultime notizie
Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress - simplywall.st
Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3 - simplywall.st
Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported - Stock Titan
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow Health at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
HROW: Record growth and expanding ophthalmic portfolio drive optimism for future launches - TradingView
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions - Investing.com Canada
Harrow Health Projects Robust Growth After Strong 2025 - TipRanks
HARROW INCHROW 8 5/8 04/30/26 (HROWL) Earnings History & Surprises - ChartMill
Is Harrow Inc. stock a top pick in earnings seasonTrade Performance Summary & Safe Entry Point Alerts - Naître et grandir
Harrow, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-03-06 - Seeking Alpha
Has The Recent Slide In Harrow (HROW) Opened A Valuation Opportunity For Investors - simplywall.st
HC Wainwright Issues Negative Forecast for Harrow Earnings - MarketBeat
HROWHarrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - mx.advfn.com
Buy or Sell Harrow Stock? - Trefis
A Look At Harrow (HROW) Valuation After Mixed Q4 Results And 2026 Profitability Concerns - Yahoo Finance
A Look At Harrow (HROW) Valuation After Q4 2025 Earnings Miss And Raised 2026 Spending Plans - simplywall.st
HC Wainwright Has Pessimistic Outlook of Harrow Q3 Earnings - MarketBeat
Harrow (NASDAQ:HROW) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference - The Globe and Mail
H.C. Wainwright raises Harrow Health stock price target to $70 By Investing.com - Investing.com UK
Harrow stock stabilizes after major Tuesday drop - Nashville Post
Harrow Inc (HROW) Trading 4.78% Higher on Mar 4 - GuruFocus
Cantor Fitzgerald lowers Harrow Health stock price target to $91 - Investing.com
Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat
These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga
Harrow (HROW): Today's Analyst Rating and Price Target Update | - GuruFocus
Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript - Insider Monkey
HROW: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
Does Harrow’s (HROW) TRIESENCE Cataract Trial Redefine Its Dropless Eye Care Strategy? - simplywall.st
H.C. Wainwright raises Harrow Health stock price target to $70 - Investing.com
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha
Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis
Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis
With Harrow Stock Sliding, Have You Assessed The Risk? - Trefis
Harrow 2026 slides: ophthalmic firm targets $357M revenue amid stock decline - Investing.com
Harrow (HROW) Projects Strong Growth with Expanding Ophthalmic P - GuruFocus
Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4 - Stock Titan
William Blair reiterates Harrow Health stock rating on ophthalmic growth - Investing.com
Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha
Notable Two Hundred Day Moving Average CrossHROW - Nasdaq
Why Is Eye-Disease-Focused Harrow Stock Falling Today? (UPDATED) - Benzinga
Harrow Q4 Earnings Call Highlights - MarketBeat
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat
HROW: 2025 revenue grew 36% with strong momentum and 2026 guidance set at $350M–$365M - TradingView
HROW: Strong 2025 growth and expanded sales force set the stage for accelerated 2026 revenue - TradingView
Harrow Stock Falls 21% After FDA Clears IND Application For Phase 3 Trial Of TRIESENCE - Nasdaq
Harrow Health, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Harrow Inc Azioni (HROW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):